^
Association details:
| Biomarker: | BRAF V600 |
|---|---|
| Cancer: | Melanoma |
| Drug: | Opdivo (nivolumab) (PD1 inhibitor) + indoximod (NLG8189) (IDO inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Study of Indoximod or Placebo Plus Pembrolizumab or Nivolumab for Subjects With Unresectable or Metastatic Melanoma (NLG2107)
Excerpt:
Have documentation of V600-activating BRAF mutation status or consent to BRAF V600 mutation testing during the screening period.
Trial ID:
